Acquirecelerate Target a company-wide integration with Ipsen leveraging Epizyme's epigenetic cancer programs to bolster Ipsen’s oncology portfolio post-acquisition, focusing on cross-sell opportunities for existing Ipsen customers and expanded indications.

Pipeline Expansion Position Epizyme’s growing small molecule programs as complementary assets to Ipsen’s pipeline, identifying collaboration or co-development opportunities to accelerate clinical candidates toward key hematological and solid tumor targets.

Epigenetic Advantage Highlight Epizyme’s novel epigenetic mechanisms of action to attract partnerships with CROs, academic consortia, and biotechs seeking targeted cancer therapies, especially where current standard-of-care gaps exist.

Clinical Synergy Leverage Epizyme’s clinical-stage status and prior Q2 performance signals to propose joint development and commercialization arrangements, exploring milestone-rich deals tied to specific epigenetic targets.

Funding & Growth Capitalize on the substantial funding and Ipsen acquisition backdrop to pursue strategic partnerships with larger pharma and specialty funds interested in epigenetic oncology platforms, offering co-investment or licensing options.